TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 5.14% SHAREHOLDING IN ABLYNX
July 01, 2015 01:07 ET
|
Ablynx
GHENT, Belgium, July 1, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication...
ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFa NANOBODY (OZORALIZUMAB) IN JAPAN
June 30, 2015 02:07 ET
|
Ablynx
Exclusive license agreement with Taisho Pharmaceutical Co, Ltd., to develop and commercialise ozoralizumab in Japan for the treatment of rheumatoid arthritis (RA)
Ablynx to receive an upfront...
ABLYNX ANNOUNCES PRESENTATIONS ON ITS POTENTIAL FIRST-IN-CLASS TREATMENT FOR ACQUIRED TTP, CAPLACIZUMAB, AT THE 2015 ANNUAL MEETING OF THE ISTH
June 17, 2015 01:08 ET
|
Ablynx
GHENT, Belgium, June 17, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that additional data from the post-hoc analysis of the worldwide Phase II TITAN study...
ABLYNX ANNOUNCES WARRANT EXERCISE
June 05, 2015 01:06 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, June 5, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and...
ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE
May 28, 2015 01:08 ET
|
Ablynx
GHENT, Belgium, May 28, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces it will present at the Annual Jefferies 2015 Global Healthcare Conference in New York City...
FMR LLC ANNOUNCE 5.07% SHAREHOLDING IN ABLYNX
May 26, 2015 01:07 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, May 26, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX
May 22, 2015 01:16 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, May 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
GENZYME TO COLLABORATE WITH ABLYNX ON MULTIPLE SCLEROSIS RESEARCH PROJECT
May 18, 2015 01:03 ET
|
Ablynx
GHENT, Belgium, May 18, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into an exclusive research collaboration with Genzyme, a Sanofi...
ABLYNX ANNOUNCES BUSINESS UPDATE AND FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2015
May 13, 2015 01:09 ET
|
Ablynx
REGULATED INFORMATION
Total revenue and grant income up 26% to €14.1 million
Key clinical programmes moving forward
More than 20 collaborative programmes advancing with all six...
ABLYNX PRESENTS UNIQUE NANOBODY DRUG INHALATION TECHNOLOGY AT THE RESPIRATORY DRUG DELIVERY EUROPE 2015 CONFERENCE
May 07, 2015 01:12 ET
|
Ablynx
GHENT, Belgium, May 7, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] presented an overview of its unique and versatile Nanobody platform and its application for inhaled...